3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Ovarian Neoplasms
5
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Interventions
padeliporfin
5
Abiraterone Acetate
3
Pluvicto
2
Paclitaxel
2
sipuleucel-T
1
rucaparib
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
ixabepilone
1
gallium 68 PSMA-11
1
apalutamide
1
abiraterone
1
Therapeutics
1
Suspensions
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Powders
1
Nivolumab
1
Leuprolide
1
Ipilimumab
1
Imatinib Mesylate
1
EPI-506
1
Chemical Fractionation
1
Biopsy, Needle
1
BAY 86-7548
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
rucaparib
×
Genitourinary
×
Clear all
NCT04676334
2024-05-07
CATCH-R
pharmaand GmbH
Phase 3
Completed
34 enrolled
9 charts